WAREMOSS LIMITED

Company number 01434575 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Financial Health Score: C — Guarded / Satisfactory on available evidence

This grade reflects the company’s administrative and structural position, not a verified assessment of profitability or solvency. WAREMOSS LIMITED has been active for approximately 46 years, is not in any formal insolvency process, and its statutory filings appear to be up to date. However, the data provided does not include profit, loss, or balance sheet figures, so a true financial diagnosis cannot be completed from this information alone. The score is therefore cautious: the company shows no visible signs of distress in the administrative record, but its underlying financial strength is unconfirmed.


Key Vital Signs

Indicator Observed Value Interpretation
Legal status Active; not in liquidation, administration, or receivership No formal insolvency proceedings are recorded. This is equivalent to a stable pulse.
Company age Incorporated 3 July 1979 (~46 years) Long-term existence suggests resilience and an established trading history.
Accounts filing Last made up 31 August 2025; next due 31 May 2027; not overdue Statutory accounts are current, like attending regular check-ups.
Confirmation statement Last made up 7 September 2026; next due 21 September 2027; not overdue Company details are being maintained on the public record.
Share capital £30,000 Modest nominal capital. For a trading business, this provides only a limited initial cushion and should be considered alongside retained profits and borrowings.
Group status Files group accounts The company operates within a wider corporate structure, which can make the financial picture more complex than a standalone entity.
Sector (SIC 47730) Dispensing chemist in specialised stores Healthcare retail is generally defensive, with steady demand, but it also involves inventory holding and regulatory obligations.

Missing vital signs: The dataset does not contain turnover, gross profit, operating profit, cash at bank, debtors, creditors, current assets, current liabilities, or net assets. Without these, it is not possible to calculate liquidity ratios (such as the current ratio), profitability margins, or cash coverage of debts.


Diagnosis

From the available record, WAREMOSS LIMITED presents as an administratively compliant, long-standing private company with no recorded insolvency proceedings. The “symptoms” visible in the filing history are normal: accounts and confirmation statements are up to date, and there is no indication of winding-up action or administration.

However, the absence of financial statement data means the following cannot be assessed:

  • Whether the company is profitable or loss-making
  • Whether it generates sufficient cash to meet day-to-day obligations
  • Whether current assets comfortably cover current liabilities (working capital health)
  • Whether the modest share capital is supported by adequate retained earnings or external funding

The group accounts status is a relevant clinical detail: the numbers filed at Companies House may reflect the position of several entities combined, so a reader should not assume the parent company’s standalone position mirrors the group total without reviewing the individual balance sheets.

Prognosis: The outlook is stable on the evidence of continued existence and filing compliance, but it is indeterminate from a financial performance standpoint. If the latest accounts reveal weak liquidity or sustained losses, the prognosis would deteriorate; if they show consistent profits and healthy cash reserves, the long-term outlook would be favourable. The next set of accounts will be the critical diagnostic test.


Recommendations

  1. Obtain the latest filed annual accounts (group accounts made up to 31 August 2025) and review the profit and loss account and balance sheet in full.
  2. Calculate core ratios once the figures are available: current ratio (current assets ÷ current liabilities), gross profit margin, and cash as a proportion of monthly operating costs.
  3. Prepare a 12-month cash flow forecast to confirm the company can pay suppliers, staff, and taxes as they fall due.
  4. Review working capital carefully, particularly inventory and debtor levels, which are typically significant for a dispensing chemist business.
  5. Maintain filing discipline to ensure accounts and confirmation statements continue to be submitted on time, avoiding penalties and preserving a clean regulatory record.

Perspective: Financial Health Diagnostician · Model: nvidia/nemotron-3.5-super-vl:free · Generated 6 November 2026